Introduction
============

Gastric cancer (GC) is the fifth most common malignant tumor of the digestive tract and the third most common cause of cancer-related death worldwide[@B1], [@B2]. Most patients with GC are diagnosed at advanced stages of the disease, and thus have lost the best opportunities for treatment[@B3]. Despite gradual declines in the incidence of and mortality from GC in recent years, the overall prognosis of GC has not improved significantly[@B4]. Thus, exploring highly specific and sensitive biomarkers and identifying new molecular targets may not only help clinicians predict prognosis, but also help clarify the mechanism underlying gastric tumorigenesis, which has profound significance for the development of new drug targets.

Fibronectin type III domain containing 1 (FNDC1) is a protein-coding and disease-related gene, also known as AGS8, FNDC2, or MEL4B, which contains the conserved fibronectin type III domain of fibronectin (FN)[@B5]-[@B7]. FN is an important type of extracellular matrix (ECM) protein and a well-known regulator of tumorigenesis that is involved in cell proliferation, migration, and invasion in several human tumors[@B8]-[@B10]. Liu et al.[@B11] reported that FN may play a critical role in the modulation of cell proliferation and invasion via mTOR signaling activation in gallbladder cancer progression. Moreover, Vizoso and colleagues[@B12] found that breast cancer cells with distant metastases frequently expressed intracellular FN, and that FN expression by tumor cells was associated strongly with matrix metalloprotease expression by stromal mononuclear inflammatory cells, which may represent crosstalk that is of prognostic relevance in breast cancer. However, a limited number of studies have examined the function of FNDC1. Although reports have described the potential role of FNDC1 in inflammation and hypoxia-induced apoptosis of cardiomyocytes[@B13], [@B14], the expression levels of FNDC1 in malignant tumors, especially in GC, have not been well defined.

Therefore, in the present study, the Cancer Genome Atlas (TCGA) and Oncomine databases were used to compare the expression levels of FNDC1 mRNA in GC and normal gastric tissue. In addition, the Kaplan-Meier plotter database was used to evaluate the prognostic significance of FNDC1 expression in patients with GC. Moreover, a tissue microarray (TMA) was used to examine the expression level of FNDC1 protein in 90 GC cases, and its prognostic value was further investigated using Kaplan-Meier and Cox survival analyses.

Materials and Methods
=====================

Bioinformatic mining methods
----------------------------

The cancer-related public databases Oncomine and TCGA were used to predict the expression levels of FNDC1 in GC and normal gastric tissue. In the Oncomine database, we entered the gene name "FNDC1" and chose the differential gene analysis module (GC versus normal) to retrieve the results. Expression of FNDC1 between primary GC and normal gastric tissue was also reviewed using the GEPIA browser (<http://gepia.cancer-pku.cn/>), which is an online tool for the analysis of data provided by TCGA and the GTEx projects[@B15]. The association between FNDC1 expression and overall survival (OS) was analyzed by data mining in the Kaplan-Meier plotter database (<http://kmplot.com>), which is an online database that enables validation of survival-associated GC biomarkers using transcriptomic data from 1065 patients[@B16]. The median FNDC1 expression was used as the cutoff. Hazard ratios with 95% confidence intervals and log-rank *P* values were calculated.

KEGG pathway analysis using the cBioPortal database
---------------------------------------------------

The genes co-expressed with FNDC1 in GC (absolute Pearson\'s *r* ≥ 0.5) were identified using the cBioPortal database (<http://www.cbioportal.org/>). Then, the co-expressed genes were loaded into ClueGo in Cytoscape for analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways[@B17]. Only pathways with *P* values ≤ 0.05 were included.

GC tissue and patient clinical information
------------------------------------------

A human TMA (cat no. HStmA180Su09) containing paired tumor and normal tissue samples from 90 cases was purchased from Shanghai Outdo Biotech Co., Ltd. (Shanghai, China). Detailed clinical characteristics, including patient age and sex, tumor size, histologic differentiation, and TNM stage, are shown in Table [1](#T1){ref-type="table"}. All patients with GC received radical surgery between December 2009 and June 2010, with ultimate follow-up through June 2016. Patients who underwent chemotherapy or radiotherapy before the surgery were excluded from the study.

Immunohistochemistry and interpretation of the results
------------------------------------------------------

Immunohistochemical staining was performed according to the manufacturer\'s protocol to examine the expression levels of FNDC1 in GC and matched normal tissue. An FNDC1 rabbit polyclonal antibody was purchased from Absin Corporation (abs127634a; Absin, China) and used at a dilution of 1:500. Two pathologists independently evaluated immunostaining of each tissue section in a double-blind manner. The immunoreactive score (IRS) for each slice was calculated by multiplying the staining intensity in four gradations (0, negative; 1, weak; 2, moderate; 3, strong) with the percentage of positive cells in five gradations (0, negative; 1, \< 10%; 2, 10%-50%; 3, 51%-80%; 4, \> 80%), each specimen was measured in three different magnification fields[@B18]. IRS ranged from 0 to 12, with IRS \> 4 indicating high FNDC1 expression and IRS ≤ 4 indicating low FNDC1 expression.

Statistical analysis
--------------------

The SPSS 24.0 software (SPSS, Inc., Chicago, IL, USA) was used to analyze the experimental data. Quantitative data were presented as means ± standard deviations. The differential expression levels of FNDC1 mRNA between the GC group and the normal tissue group from TCGA and Oncomine databases were analyzed using the independent-samples *t* test. The chi-squared test was performed to analyze the relationship between FNDC1 expression level and clinicopathological parameters. IRS scores of FNDC1 staining in tumor and adjacent non-tumor gastric tissues were compared by Wilcoxon rank-sum test. Kaplan-Meier survival analyses were performed using the log-rank test, and a Cox regression model was established for a multivariate survival analysis to determine prognostic factors using variables that were significant in the univariate analysis. *P* values \< 0.05 were considered to indicate statistical significance.

Results
=======

Overexpression of FNDC1 mRNA and protein levels in GC
-----------------------------------------------------

TCGA and Oncomine database data were used to examine the differential expression levels of FNDC1 mRNA between GC and normal gastric tissue. The FNDC1 mRNA expression level was dramatically higher in GC tissue than in normal gastric tissue (all *P* \< 0.05, Figure [1](#F1){ref-type="fig"}A-H). To confirm the predictive results, immunohistochemical assays were performed to examine FNDC1 protein levels in 90 cases of GC with paired adjacent tissue (Figure [2](#F2){ref-type="fig"}A, B). The mean ± standard deviation IRS scores of FNDC1 in cancerous tissue and adjacent normal tissue were 5.822 ± 2.368 and 4.526 ± 2.219, respectively. The IRS scores of FNDC1 in tumors were much higher than those in adjacent non-tumor gastric tissues (*P* \< 0.001; Figure [2](#F2){ref-type="fig"}C and Supplementary Table [S1](#SM0){ref-type="supplementary-material"}-S2), indicating that the expression level of FNDC1 protein was significantly higher in GC tissues than in paired normal tissues.

Relationships between FNDC1 and clinicopathological parameters of patients with GC
----------------------------------------------------------------------------------

Relationships between FNDC1 protein expression and clinicopathological parameters of patients with GC (age, sex, tumor site, tumor size, histological grade, neural/vascular invasion, lymph node metastasis, and TNM stage) were investigated. The differential expression level of FNDC1 protein (low versus high) was associated significantly with sex and TNM stage in patients with GC (all *P* \< 0.05; Table [1](#T1){ref-type="table"}).

High FNDC1 expression is associated with poor OS of patients with GC
--------------------------------------------------------------------

The prognostic significance of FNDC1 expression levels in patients with GC was investigated. Through data mining in TCGA database and the Kaplan-Meier plotter, we found that OS was significantly lower among patients with GC with high expression of FNDC1 mRNA than among those with low expression, using the median as the cutoff value (all *P* \< 0.01; Figure [3](#F3){ref-type="fig"}A, B). As FNDC1 is a protein-coding gene, to confirm the predictive results, we also analyzed the immunohistochemical staining results and found that OS was significantly lower among patients with GC with high expression of FNDC1 protein than among those with low expression (*P* = 0.007; Figure [3](#F3){ref-type="fig"}C). As shown in Table [1](#T1){ref-type="table"}, the differential expression level of FNDC1 protein (low versus high) was significantly associated with TNM stage, so we further investigated the relationship between FNDC1 protein expression level and OS of GC patients stratified by clinical stage, but found no statistical significance (*P* = 0.2508 for stage I-II, Figure [3](#F3){ref-type="fig"}D; *P* = 0.1770 for stage III-IV, Figure [3](#F3){ref-type="fig"}E). In addition, a Cox univariate survival analysis revealed that FNDC1 expression, tumor location, tumor size, lymph node metastasis, and TNM stage were significant parameters affecting the survival time of patients with GC (Table [2](#T2){ref-type="table"}). These five significant factors were subsequently substituted into the multivariate Cox survival analysis, which indicated that high FNDC1 expression level and large tumor size were independent predictors of unfavorable prognosis in patients with GC (all*P* \< 0.05; Table [3](#T3){ref-type="table"}).

KEGG pathway analysis of FNDC1 and its co-expressed genes in TCGA-STAD
----------------------------------------------------------------------

Data mining using cBioPortal for TCGA was used to identify 1212 genes significantly co-expressed with FNDC1. A total of 265 genes were selected by setting absolute Pearson\'s *r* ≥ 0.5 as a threshold. Then, the genes were subjected to enrichment analysis with the KEGG pathways; we found that the genes were enriched in the following: steroid hormone biosynthesis, malaria, proteoglycans in cancer, Wnt signaling pathway, protein digestion and absorption, hedgehog signaling pathway, hippo signaling pathway, basal cell carcinoma, PI3K-Akt signaling pathway, focal adhesion, ECM-receptor interaction, relaxin signaling pathway, AGE-RAGE signaling pathway in diabetic complications, amoebiasis, human papillomavirus infection, and small cell lung cancer (Figure [4](#F4){ref-type="fig"}A-C; Table [4](#T4){ref-type="table"}). The most significant pathway was ECM-receptor interaction (*P* = 3.93E-12; Table [4](#T4){ref-type="table"}).

Discussion
==========

The FNDC1 gene is located in the 6q25.3 human chromosomal region, and was first identified as a differentially expressed mRNA from human dermal fibroblasts. The biological function of FNDC1 has yet to be well defined, and the majority of studies concerning FNDC1 have shown it may play an important role in inflammation. The minor (T) allele of SNP rs2392989 was reported to confer a higher risk of acute otitis media and to be correlated with higher expression of FNDC1[@B6]. In addition, FNDC1 expression in the mouse middle ear was upregulated upon lipopolysaccharide treatment, which is known to be a potent inducer of inflammation through stimulation of transforming growth factor-![](jcav09p4586i003.jpg), tumor necrosis factor-![](jcav09p4586i004.jpg), and interleukin-1 signaling[@B19]. To date, the only functional study of FNDC1 in human cancer was reported by Das and colleagues[@B5]. They discovered that miR-1207-3p was significantly under-expressed in prostate cancer (PCa) cell lines in comparison with normal prostate epithelial cells, and that increased expression of microRNA-1207-3p significantly inhibited proliferation and migration, and induced apoptosis of PCa cells via direct targeting of FNDC1. They also revealed significant overexpression of FNDC1, fibronectin (FN1), and the androgen receptor in human PCa cell lines and tissue, which was correlated positively with aggressive PCa. However, the expression level of FNDC1 and its potential clinical significance in GC have not been well defined.

In the current study, we first used bioinformatics to predict the high expression of FNDC1 in gastric adenocarcinoma tissue compared with normal gastric tissue using the Oncomine and TCGA public databases. Then, immunohistochemistry was used to verify that FNDC1 protein expression levels were significantly higher in the GC tissue group compared with the normal tissue group. These results were consistent with those of bioinformatic predictions and suggested that FNDC1 acts as an oncogene by promoting the development of gastric adenocarcinoma. Subsequently, the clinical prognostic significance of FNDC1 gene expression levels in patients with GC was examined. First, differential expression levels of FNDC1 protein were associated significantly with sex and TNM stage in patients with GC. Moreover, a Kaplan-Meier univariate survival analysis showed that, compared with those with low FNDC1 mRNA and protein expression levels, patients with GC with high FNDC1 expression levels had remarkably shorter OS. A multivariate Cox analysis showed that high expression of FNDC1 and advanced TNM stage were independent predictors of unfavorable prognosis in patients with GC. Our results also showed that the genes co-expressed with FNDC1 in GC were most enriched in ECM-receptor interactions. It is well known that the complex interactions between tumor cells and the ECM may play important roles in tumor metastasis, including cell differentiation, migration, cytoskeletal reorganization, and morphological transition[@B20], [@B21]. According to previous reports[@B22], [@B23], FN is considered a key element in ECM components and plays an important role in cancer cell proliferation, differentiation, and migration. As FNDC1 contains the conserved fibronectin type III domain of FN, we inferred that FNDC1 may play an important role in human cancer tumorigenesis. All of these findings indicate that FNDC1 was over-expressed in GC tissue and that high levels of FNDC1 expression could indicate poor prognosis for patients with GC. Thus, this gene may be a key target involved in the growth and metastasis of GC.

However, this study is not without limitations. First, the cases used were collected non-sequentially, which may have resulted in selection bias and influenced the final statistical results. Next, tissue from only 90 cases was used in this study, which was a small sample. In addition, some clinicopathological data associated with GC, such as disease-free survival, were not included. Lastly, although KEGG pathway analysis indicated that the genes co-expressed with FNDC1 were enriched in ECM-receptor interactions, the detailed underlying molecular mechanisms have not been determined. The above limitations should be addressed in future studies.

Conclusions
===========

In conclusion, our study revealed that FNDC1 was highly expressed in GC, and overexpression of FNDC1 was an independent predictor of reduced prognosis in patients with GC. FNDC1 co-expressed genes are largely enriched in ECM-receptor interactions, which are related to tumor metastasis. FNDC1 may be a potential prognostic biomarker and therapeutic target for GC in the future.
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![**Overexpression of FNDC1 in gastric cancer predicted using GEO and TCGA data.** FNDC1 mRNA levels of GC versus normal gastric tissue in (**A**, **B**) DErrico Gastric (GEO: GSE13911), (**C**-**F**) Cho Gastric (GEO: GSE13861), (**G**) Wang Gastric (GEO: GSE19826), and (**H**) TCGA and GTEx databases. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. DGA, diffuse gastric adenocarcinoma; GMA, gastric mixed adenocarcinoma; GITA, gastric intestinal type adenocarcinoma; GA, gastric adenocarcinoma.](jcav09p4586g001){#F1}

![**FNDC1 immunoreactivity was higher in gastric cancer tissues than in adjacent normal tissues.** (**A**) Representative high expression of FNDC1 in GC tissue (HE, 200![](jcav09p4586i001.jpg)); (**B**) Representative low expression of FNDC1 in matched adjacent normal tissue (HE, 200![](jcav09p4586i002.jpg)). (**C**) The IRS in tumor tissues were statistically higher than that in adjacent normal tissues. \*\*\**P* \< 0.001. IRS, immunoreactive score; GC, gastric cancer; NT, normal tissue; HE, hematoxylin and eosin.](jcav09p4586g002){#F2}

![**Kaplan-Meier curves of OS of patients with gastric adenocarcinoma based on FNDC1 mRNA and protein expression (low versus high). (A)** Relationship between FNDC1 mRNA expression level and OS of patients with GC based on TCGA data. **(B)** Relationship between FNDC1 mRNA expression level and OS of patients with GC based on GEO data (GSE22377, GSE14210, GSE51105). **(C)** Relationship between FNDC1 protein expression level and OS of patients with GC based on immunohistochemical staining. **(D)** Relationship between FNDC1 protein expression level and OS of GC stage I-II. **(E)** Relationship between FNDC1 protein expression level and OS of GC stage III-IV. OS, overall survival; GC, gastric cancer.](jcav09p4586g003){#F3}

![**Enrichment of FNDC1 and its co-expressed genes in KEGG pathways.** (**A**) Bar chart and (**B**) pie chart of the enrichment of FNDC1 and its co-expressed genes in KEGG pathways. (**C**) The network of FNDC1 and its co-expressed genes in KEGG pathways.](jcav09p4586g004){#F4}

###### 

Relationship between FNDC1 levels and clinicopathological parameters of GC patients.

  Clinicopathological parameters     Cases(N)   FNDC1 expression level   χ^2^   *P* value   
  ---------------------------------- ---------- ------------------------ ------ ----------- -------
  **Age at surgery (years)**                                                                
  \<60                               27         9                        18                 
  ≥60                                63         16                       47     0.593       0.441
  **Gender**                                                                                
  Female                             22         10                       12                 
  Male                               68         15                       53     4.535       0.033
  **Tumor location**                                                                        
  Antrum                             38         11                       27                 
  Other sites                        52         14                       38     0.045       0.832
  **Tumor size (cm)**                                                                       
  \<5                                36         13                       23                 
  ≥5                                 53         12                       41     1.926       0.165
  **Histological differentiation**                                                          
  Well                               29         8                        21                 
  Moderate/poor                      61         17                       44     0.001       0.978
  **Neural/vascular invasion**                                                              
  No                                 72         19                       53                 
  Yes                                18         6                        12     0.346       0.556
  **Lymph node metastasis (n)**                                                             
  \<3                                38         14                       24                 
  ≥3                                 52         11                       41     2.694       0.101
  **TNM stage**                                                                             
  I-II                               36         16                       20                 
  III-IV                             54         9                        45     8.308       0.004

###### 

Cox univariate survival analysis of FNDC1 and other clinicopathological parameters in GC patients.

  Clinicopathological parameters     Mean survival time (months)   95% CI          *P* value
  ---------------------------------- ----------------------------- --------------- -----------
  **FNDC1 expression**                                                             
  Low                                54.053                        42.469-65.636   0.006
  High                               34.522                        27.582-41.461   
  **Age (years)**                                                                  
  \<60                               49.119                        37.251-60.986   0.081
  ≥60                                35.719                        28.607-42.831   
  **Gender**                                                                       
  Female                             42.182                        28.761-55.603   0.521
  Male                               38.984                        31.985-45.983   
  **Tumor location**                                                               
  Antrum                             46.184                        35.984-56.384   0.043
  Other sites                        34.978                        27.396-42.561   
  **Tumor size (cm)**                                                              
  \<5                                54.435                        44.577-64.294   0.000
  ≥5                                 28.918                        22.085-35.751   
  **Lymph node metastasis (n)**                                                    
  \<3                                51.588                        41.985-61.190   0.002
  ≥3                                 30.963                        23.591-38.335   
  **Neural/vascular invasion**                                                     
  No                                 41.345                        34.489-48.202   0.517
  Yes                                33.374                        18.867-47.881   
  **Histological differentiation**                                                 
  Well                               48.069                        37.481-58.657   0.133
  Moderate/poor                      35.780                        28.274-43.286   
  **TNM stage**                                                                    
  I-II                               54.287                        44.729-63.845   0.000
  III-IV                             29.908                        22.781-37.036   

###### 

Cox multivariate analysis of FNDC1 and other clinicopathological parameters in GC patients.

  Covariates                                  HR      95% CI for HR   *P* value
  ------------------------------------------- ------- --------------- -----------
  FNDC1 expression level (low *vs.* high)     2.143   1.069-4.297     0.032
  Tumor location (antrum *vs.* other sites)   1.452   0.841-2.508     0.181
  Tumor size (\<5 *vs.* ≥5 cm)                2.259   1.129-4.522     0.021
  Lymph node metastasis (\<3 *vs.* ≥3)        1.212   0.515-2.853     0.660
  TNM stage (I-II *vs.* III-IV)               1.232   0.492-3.086     0.656

###### 

KEGG pathway analysis of FNDC1 and its co-expressed genes in TCGA-STAD.

  GOID    GOTerm                                                 Term PValue   Group PValue   \% Associated Genes   Nr. Genes   Associated Genes Found
  ------- ------------------------------------------------------ ------------- -------------- --------------------- ----------- ----------------------------------------------------------------------------------------------------------------------------------------
  00140   Steroid hormone biosynthesis                           4.62E-02      4.62E-02       5.17                  3.00        \[CYP1B1, CYP7B1, HSD11B1\]
  05144   Malaria                                                5.46E-04      5.46E-04       10.20                 5.00        \[LRP1, TGFB3, THBS1, THBS2, THBS3\]
  05205   Proteoglycans in cancer                                1.94E-03      1.94E-03       4.43                  9.00        \[DCN, FN1, FZD1, LUM, MMP2, THBS1, TIMP3, TWIST2, WNT2\]
  04310   Wnt signaling pathway                                  3.60E-03      3.60E-03       4.90                  7.00        \[FZD1, PRICKLE1, SERPINF1, SFRP2, SFRP4, SOX17, WNT2\]
  04974   Protein digestion and absorption                       1.47E-11      1.47E-11       15.56                 14.00       \[COL10A1, COL12A1, COL15A1, COL18A1, COL1A1, COL1A2, COL3A1, COL4A2, COL5A1, COL5A2, COL6A1, COL6A2, COL6A3, ELN\]
  04340   Hedgehog signaling pathway                             4.49E-04      9.75E-05       10.64                 5.00        \[EVC, GAS1, GLI1, GLI2, GLI3\]
  04390   Hippo signaling pathway                                5.40E-03      9.75E-05       4.55                  7.00        \[CTGF, DLG4, FZD1, GLI2, LATS2, TGFB3, WNT2\]
  05217   Basal cell carcinoma                                   1.73E-03      9.75E-05       7.94                  5.00        \[FZD1, GLI1, GLI2, GLI3, WNT2\]
  04151   PI3K-Akt signaling pathway                             1.21E-06      4.05E-05       5.13                  18.00       \[COL1A1, COL1A2, COL4A2, COL6A1, COL6A2, COL6A3, FGF7, FN1, ITGA11, LAMA2, LAMA4, LAMB1, PDGFRA, PDGFRB, THBS1, THBS2, THBS3, VEGFC\]
  04510   Focal adhesion                                         1.42E-09      4.05E-05       8.54                  17.00       \[COL1A1, COL1A2, COL4A2, COL6A1, COL6A2, COL6A3, FN1, ITGA11, LAMA2, LAMA4, LAMB1, PDGFRA, PDGFRB, THBS1, THBS2, THBS3, VEGFC\]
  04512   ECM-receptor interaction                               3.93E-12      4.05E-05       17.07                 14.00       \[COL1A1, COL1A2, COL4A2, COL6A1, COL6A2, COL6A3, FN1, ITGA11, LAMA2, LAMA4, LAMB1, THBS1, THBS2, THBS3\]
  04926   Relaxin signaling pathway                              9.17E-03      4.05E-05       4.62                  6.00        \[COL1A1, COL1A2, COL3A1, COL4A2, MMP2, VEGFC\]
  04933   AGE-RAGE signaling pathway in diabetic complications   8.17E-06      4.05E-05       9.09                  9.00        \[COL1A1, COL1A2, COL3A1, COL4A2, FN1, MMP2, NOX4, TGFB3, VEGFC\]
  05146   Amoebiasis                                             7.05E-07      4.05E-05       10.42                 10.00       \[COL1A1, COL1A2, COL3A1, COL4A2, FN1, IL1R1, LAMA2, LAMA4, LAMB1, TGFB3\]
  05165   Human papillomavirus infection                         1.47E-06      4.05E-05       5.33                  17.00       \[COL1A1, COL1A2, COL4A2, COL6A1, COL6A2, COL6A3, FN1, FZD1, ITGA11, LAMA2, LAMA4, LAMB1, PDGFRB, THBS1, THBS2, THBS3, WNT2\]
  05222   Small cell lung cancer                                 9.22E-03      4.05E-05       5.38                  5.00        \[COL4A2, FN1, LAMA2, LAMA4, LAMB1\]

[^1]: \*These authors contributed equally to this work

[^2]: Competing Interests: The authors have declared that no competing interest exists.
